Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Fig. 3

Adjusted annualized relapse rate (ARR) by 6-month intervals. Results from the SELECT placebo group have been published previously [3]. Adjusted ARR in SELECTED was estimated from a Poisson regression adjusted for the number of relapses in the year before study entry. Rates were estimated by time interval from the first dose of daclizumab received. *Gold et al. [3]

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us